174 completed, 20 terminated, 19 unknown, 5 withdrawn. 83 Phase 3, 70 Phase 4, 24 Not applicable, 23 Phase 1, 13 Phase 2.
Follow glimepiride: new trials by email Literature Review of glimepiride trials Research Report on glimepiride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients empagliflozin 10mg, Glimepiride 1mg - Diabete Type 2 | Phase 4 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 200 | 2026-03-01 | 2026-01-26 |
| Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3 Implementation of program based on WHO HEARTS-D guidelines, Metformin, Glimepiride - Diabete Mellitus | Not applicable | Recruiting | Washington University School of Medicine | 2800 | 2026-02-14 | 2026-10-16 |
| Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction. Glimepiride (oral), Placebo - Type 2 Diabetes Mellitus (T2DM), Chronic Heart Failure (CHF) | Phase 3 | Not yet recruiting | Tongji Hospital | 1484 | 2026-01-01 | 2025-12-17 |
| Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes SGLT2 inhibitor, Glimepiride - Diabetes Mellitus, Cellular Senescence | Phase 4 | Unknown | Yonsei University | 92 | 2023-06-01 | 2024-05-09 |
| Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), (A2) Glimepiride/Vildagliptin/Metformin - Type 2 Diabetes | Phase 3 | Completed | Laboratorios Silanes S.A. de C.V. | 162 | 2023-03-21 | 2025-06-10 |
| Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients Vildagliptin 50 MG, Glimepiride 3 Mg Oral Tablet - Type 2 Diabetes | Not applicable | Completed | Damanhour University | 70 | 2022-10-01 | 2025-02-04 |
| The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes Glimepiride, Sitagliptin - Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes | Phase 4 | Unknown | Peking University People's Hospital | 192 | 2022-01-01 | 2022-05-23 |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA - Cardiovascular Events, Type2 Diabetes | Active not recruiting | Brigham and Women's Hospital | 781430 | 2021-08-01 | 2026-08-13 | |
| Comparison of Type 2 Diabetes Pharmacotherapy Regimens SU, DPP4, SGLT2i - Type 2 Diabetes Mellitus, Cardiovascular Diseases | Completed | Kaiser Permanente | 241981 | 2021-07-01 | 2025-11-21 | |
| Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus Dapagliflozin 5Mg Tab, Glimepiride 4Mg Tab - Diabetes Mellitus, Type 2 | Completed | Damanhour University | 60 | 2020-12-01 | 2023-04-18 | |
| Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Glimepiride Tablets, glimepiride plus fenofibrate, glimepiride plus curcumin - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Rehab Werida | 60 | 2020-11-01 | 2022-03-04 |
| Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects Glimepiride, Amaryl® - Drug Use | Not applicable | Completed | PT Harsen Laboratories | 34 | 2020-09-21 | 2022-07-21 |
| Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents Glucophage 500Mg Tablet, Acarbose Tablets, Sitagliptin tablet - Type2 Diabetes Mellitus | Phase 4 | Unknown | Peking Union Medical College Hospital | 180 | 2020-03-02 | 2020-02-27 |
| Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes Gemigliptin, Glimepiride - Ejection Fraction | Phase 4 | Unknown | Seoul National University Bundang Hospital | 80 | 2020-01-01 | 2023-03-08 |
| Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data Glimepiride, Liraglutide - Diabetes | Completed | Brigham and Women's Hospital | 3474 | 2019-09-01 | 2023-07-27 | |
| Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin Rosuvastatin10 mg tablet, Placebo Oral Tablet - Diabetes Mellitus, Type 2 | Not applicable | Completed | Rehab Werida | 70 | 2019-04-01 | 2023-04-14 |
| Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral, Glimepiride - Diabetic Patients | Not applicable | Completed | Damanhour University | 70 | 2019-01-31 | 2023-11-22 |
| Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD Vildagliptin 50 mg Oral Tablet, Metformin 1000 mg Oral Tablet, Glimepiride upto 4 mg Oral Tablet - Coronary Artery Disease, Diabetes Mellitus, Type 2 | Phase 4 | Completed | Damanhour University | 80 | 2018-10-08 | 2023-06-13 |
| Replication of the GRADE Diabetes Trial in Healthcare Claims Data Sitagliptin, Glimepiride - Diabetes | Completed | Brigham and Women's Hospital | 6403 | 2018-09-01 | 2023-07-27 | |
| Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy Sotagliflozin (SAR439954), Glimepiride, Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Lexicon Pharmaceuticals | 954 | 2017-12-01 | 2021-05-11 |
Showing 20 of 222. Sign in to see all of them.
Diabetes Mellitus, Type 2 (178) · Diabetes Mellitus (51) · Insulin Resistance (9) · Glucose Metabolism Disorders (5) · Cardiovascular Diseases (4) · Diabetes Mellitus, Lipoatrophic (4) · Dyslipidemias (4) · Hypoglycemia (4) · Atherosclerosis (3) · Glucose Intolerance (3) · Coronary Disease (2) · Heart Failure (2) · Maturity-Onset Diabetes of the Young, Type 3 (2) · Coronary Artery Disease (1) · Diabetic Ketoacidosis (1)
Merck Sharp & Dohme LLC (24) · Sanofi (17) · Novo Nordisk A/S (15) · Takeda (13) · AstraZeneca (8) · Boehringer Ingelheim (8) · GlaxoSmithKline (7) · Handok Inc. (6) · Eli Lilly and Company (5) · Laboratorios Silanes S.A. de C.V. (5) · Novartis Pharmaceuticals (5) · Damanhour University (4) · Seoul National University Bundang Hospital (4) · Brigham and Women's Hospital (3) · Canadian Network for Observational Drug Effect Studies, CNODES (3)
United States (56) · South Korea (37) · Germany (31) · Mexico (25) · Canada (20) · Poland (19) · United Kingdom (19) · India (18) · Russia (17) · Spain (17) · Czechia (15) · Hungary (15) · Italy (15) · Sweden (15) · China (14)
Pierre Ernst, MD, MSc (3) · Benoit Girard, MD (2) · In-Jin Jang, Professor (2) · James D Carlson, Pharm. D. (2) · Ji Young Ahn (2)
PMID 25504028, PMID 23010561, PMID 21450987, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 19245711, PMID 19491536, PMID 19878259, PMID 21883806, PMID 22055210, PMID 22193143, PMID 22862847, PMID 23186975, PMID 24561125, PMID 32700393, PMID 34213819, PMID 21209033, PMID 31064361, PMID 10454950, PMID 1490793, PMID 18539917, PMID 19491535, PMID 19744248, PMID 19898642, PMID 19930006, PMID 22234149, PMID 24843617, PMID 28683300, PMID 30880443, PMID 33367811, PMID 36573717, PMID 36763328, PMID 37435938, PMID 38770818, PMID 40020703, PMID 8569826, PMID 9209206, PMID 9793597, PMID 11347758, PMID 14583175, PMID 15161785, PMID 16033281, PMID 16043738, PMID 16504835, PMID 16612330, PMID 16627388, PMID 16784922
2009 (5), 2005 (2), 2016 (2), 2014 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), R01HL144708 (1), U01DK098246 (1)